Phase 2 Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have given signed written consent before enrolling
- People aged 18 years or older
- People with a good general health and activity level (ECOG performance score of 0 or 1, meaning fully active or able to carry out light work)
- People newly diagnosed with a specific stage of breast cancer (T1c N1-2 or T2-3 N0-2 — confirm exact staging details with the trial site)
- People whose breast cancer is "triple-negative" and has a PD-L1 CPS score below 10 (a specific laboratory marker measured from the tumour)
- People whose blood counts meet certain minimum levels — including haemoglobin, white blood cells (neutrophils), and platelets
- People whose kidney function blood tests are within an acceptable range (BUN and creatinine no more than 1.5 times the upper limit of normal)
- People whose liver function blood tests are within an acceptable range (bilirubin, ALP, AST, and ALT at acceptable levels)
- Women who could become pregnant and are willing to use contraception throughout the study
- Women who have had a negative pregnancy test (blood or urine) within 7 days before starting treatment
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with occult breast cancer (cancer that cannot be detected in the breast itself)
- People with cancer in both breasts
- People whose breast tumour is not suitable for a type of targeted radiation therapy called SBRT (confirm with trial site)
- People who are unable to have an MRI scan
- People with a history of another cancer that may affect their survival
- People with an active autoimmune disease, or a history of autoimmune disease
- People currently using immune-suppressing medications or systemic steroids within the 2 weeks before enrolling
- People with a known allergy to any ingredient in the study drugs
- People with serious heart symptoms or heart conditions that are not well controlled
- People with an active infection, or an unexplained fever above 38.5°C at the time of screening or before the first dose
- People with other factors that could cause them to leave the study early, such as serious ongoing illnesses, significantly abnormal lab results, or personal or family circumstances that could affect safety or data collection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13661135602
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
the efficacy of neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.